Opus Genetics, Inc. (IRD)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Opus Genetics, Inc. reported revenue of $14.20M, up 29.1% from the prior year. The company ran a net loss, with a net margin of -349.3%. It held $50.24M in total assets against $34.90M in total liabilities.
Key ratios (FY2025)
-271.9%
Operating margin
-349.3%
Net margin
-323.1%
Return on equity
+29.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.20M | $10.99M | $19.05M | $39.85M | $589.0K | $0 | — | — | — | — |
| Operating Income | -$38.60M | -$62.07M | -$10.56M | $18.23M | -$22.70M | -$19.97M | -$4.19M | -$20.54M | -$17.35M | -$16.41M |
| Net Income | -$49.59M | -$57.53M | -$9.99M | $17.89M | -$56.69M | -$24.62M | -$6.17M | -$14.37M | -$25.29M | -$9.31M |
| EPS (Diluted) | $-0.80 | $-2.15 | $-0.46 | $0.87 | $-3.82 | $-5.28 | — | — | — | — |
| Total Assets | $50.24M | $36.86M | $53.95M | $48.99M | $26.08M | $17.68M | $1.78M | $16.04M | $28.29M | $21.04M |
| Total Liabilities | $34.90M | $11.29M | $4.04M | $2.75M | $3.85M | $31.15M | $9.34M | $5.48M | $11.52M | $3.99M |
| Shareholders' Equity | $15.35M | $6.72M | $49.91M | $46.24M | $22.22M | -$13.47M | -$7.56M | -$1.70M | $16.77M | $17.06M |
| Cash & Equivalents | $45.09M | $30.32M | $50.50M | $42.63M | $24.53M | — | — | $8.74M | $8.90M | $11.58M |
| Operating Cash Flow | -$35.25M | -$25.58M | -$1.11M | $14.31M | -$19.37M | -$6.80M | -$3.59M | -$18.84M | -$15.42M | — |
| Capital Expenditures | — | — | — | — | — | $0 | $25.0K | — | — | — |
| Shares Outstanding | 69.89M | 31.57M | 23.98M | 20.86M | 18.85M | 10.88M | 2.85M | 3.12M | 31.73M | 23.74M |